Stocks · News reference
Bristol Myers Squibb presented 56-week Phase 3 clinical trial data for Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy at the HCMS Scientific Sessions.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beeline Medicines Corporation announced Phase 2 study results for afimetoran, an investigational TLR7/8 inhibitor originally discovered by Bristol Myers Squibb.
Bloomsbury Publishing has announced it will publish 'Dancing Through Life: A Broadway Memoir of Luck & Talent' by Larry Fuller in May 2027.
Aberdeen Group plc has notified Bloomsbury Publishing plc that its voting rights in the company have fallen below the 5% threshold.
Bristol Myers Squibb has triggered a clinical development milestone payment to Editas Medicine, as reported in the latter's third-quarter 2026 financial update.
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.